Search Results - "NEELAPU, Sattva"

Managing the toxicities of CAR T‐cell therapy by Neelapu, Sattva S.

“…Chimeric antigen receptor (CAR) T‐cell therapy has the potential to revolutionize the management of B‐cell lymphomas and possibly other cancers. Two anti‐CD19…”
Get full text

CAR-T efficacy: is conditioning the key? by Neelapu, Sattva S.

Get full text

Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy by Morris, Emma C., Neelapu, Sattva S., Giavridis, Theodoros, Sadelain, Michel

“…A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional anticancer agents, such as chemotherapy, radiotherapy and…”
Get full text

CAR-T failure: beyond antigen loss and T cells by Strati, Paolo, Neelapu, Sattva S.

Get full text

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study by Crump, Michael, Neelapu, Sattva S., Farooq, Umar, Van Den Neste, Eric, Kuruvilla, John, Westin, Jason, Link, Brian K., Hay, Annette, Cerhan, James R., Zhu, Liting, Boussetta, Sami, Feng, Lei, Maurer, Matthew J., Navale, Lynn, Wiezorek, Jeff, Go, William Y., Gisselbrecht, Christian

“…Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Although 5-year survival rates in the first-line setting range from…”
Get full text

CAR Treg cells: prime suspects in therapeutic resistance by Saini, Neeraj, Neelapu, Sattva S.

“…Using comprehensive single-cell profiling, two studies reveal the molecular phenotypes of CAR T cells associated with durable response in patients with…”
Get full text

A CAR against CAR for unintended consequences by Neelapu, Sattva S.

Get full text

Cancer immunotherapy: Strategies for personalization and combinatorial approaches by Sathyanarayanan, Vishwanath, Neelapu, Sattva S.

“…The results of recent clinical trials using novel immunotherapy strategies such as immune checkpoint blockade and adoptive T-cell therapy approaches including…”
Get full text

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial by Locke, Frederick L, Ghobadi, Armin, Jacobson, Caron A, Miklos, David B, Lekakis, Lazaros J, Oluwole, Olalekan O, Lin, Yi, Braunschweig, Ira, Hill, Brian T, Timmerman, John M, Deol, Abhinav, Reagan, Patrick M, Stiff, Patrick, Flinn, Ian W, Farooq, Umar, Goy, Andre, McSweeney, Peter A, Munoz, Javier, Siddiqi, Tanya, Chavez, Julio C, Herrera, Alex F, Bartlett, Nancy L, Wiezorek, Jeffrey S, Navale, Lynn, Xue, Allen, Jiang, Yizhou, Bot, Adrian, Rossi, John M, Kim, Jenny J, Go, William Y, Neelapu, Sattva S

“…Axicabtagene ciloleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. In the previous analysis of the ZUMA-1 registrational study,…”
Get full text

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial by Jacobson, Caron A, Chavez, Julio C, Sehgal, Alison R, William, Basem M, Munoz, Javier, Salles, Gilles, Munshi, Pashna N, Casulo, Carla, Maloney, David G, de Vos, Sven, Reshef, Ran, Leslie, Lori A, Yakoub-Agha, Ibrahim, Oluwole, Olalekan O, Fung, Henry Chi Hang, Rosenblatt, Joseph, Rossi, John M, Goyal, Lovely, Plaks, Vicki, Yang, Yin, Vezan, Remus, Avanzi, Mauro P, Neelapu, Sattva S

“…Most patients with advanced-stage indolent non-Hodgkin lymphoma have multiple relapses. We assessed axicabtagene ciloleucel autologous anti-CD19 chimeric…”
Get full text

The promise of CAR T-cell therapy in aggressive B-cell lymphoma by Nair, Ranjit, Neelapu, Sattva S.

“…Relapsed or refractory aggressive B-cell lymphoma has an extremely poor prognosis and efforts to develop novel therapies for these patients have failed for…”
Get full text

How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies by Reagan, Patrick M, Neelapu, Sattva S

Get full text

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities by Neelapu, Sattva S., Tummala, Sudhakar, Kebriaei, Partow, Wierda, William, Gutierrez, Cristina, Locke, Frederick L., Komanduri, Krishna V., Lin, Yi, Jain, Nitin, Daver, Naval, Westin, Jason, Gulbis, Alison M., Loghin, Monica E., de Groot, John F., Adkins, Sherry, Davis, Suzanne E., Rezvani, Katayoun, Hwu, Patrick, Shpall, Elizabeth J.

“…Key Points Chimeric antigen receptor (CAR)-T-cell therapy is a promising approach for the treatment of refractory malignancies, but is associated with unique…”
Get full text

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium by Nastoupil, Loretta J, Jain, Michael D, Feng, Lei, Spiegel, Jay Y, Ghobadi, Armin, Lin, Yi, Dahiya, Saurabh, Lunning, Matthew, Lekakis, Lazaros, Reagan, Patrick, Oluwole, Olalekan, McGuirk, Joseph, Deol, Abhinav, Sehgal, Alison R, Goy, Andre, Hill, Brian T, Vu, Khoan, Andreadis, Charalambos, Munoz, Javier, Westin, Jason, Chavez, Julio C, Cashen, Amanda, Bennani, N Nora, Rapoport, Aaron P, Vose, Julie M, Miklos, David B, Neelapu, Sattva S, Locke, Frederick L

“…Axicabtagene ciloleucel (axi-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell…”
Get full text

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study by Takahashi, Koichi, MD, Wang, Feng, PhD, Kantarjian, Hagop, Prof, Doss, Denaha, MS, Khanna, Kanhav, MS, Thompson, Erika, MS, Zhao, Li, PhD, Patel, Keyur, MD, Neelapu, Sattva, MD, Gumbs, Curtis, BS, Bueso-Ramos, Carlos, Prof, DiNardo, Courtney D, MD, Colla, Simona, PhD, Ravandi, Farhad, Prof, Zhang, Jianhua, PhD, Huang, Xuelin, PhD, Wu, Xifeng, Prof, Samaniego, Felipe, MD, Garcia-Manero, Guillermo, Prof, Futreal, P Andrew, Prof

“…Summary Background Therapy-related myeloid neoplasms are secondary malignancies that are often fatal, but their risk factors are not well understood. Evidence…”
Get full text

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors by Liu, Enli, Marin, David, Banerjee, Pinaki, Macapinlac, Homer A, Thompson, Philip, Basar, Rafet, Nassif Kerbauy, Lucila, Overman, Bethany, Thall, Peter, Kaplan, Mecit, Nandivada, Vandana, Kaur, Indresh, Nunez Cortes, Ana, Cao, Kai, Daher, May, Hosing, Chitra, Cohen, Evan N, Kebriaei, Partow, Mehta, Rohtesh, Neelapu, Sattva, Nieto, Yago, Wang, Michael, Wierda, William, Keating, Michael, Champlin, Richard, Shpall, Elizabeth J, Rezvani, Katayoun

“…Using cord blood as an allogeneic lymphocyte source, the investigators in this study infused natural killer cells that had been modified to express an…”
Get full text

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial by Westin, Jason R, MD, Chu, Fuliang, PhD, Zhang, Min, PhD, Fayad, Luis E, MD, Kwak, Larry W, Prof, Fowler, Nathan, MD, Romaguera, Jorge, Prof, Hagemeister, Fredrick, Prof, Fanale, Michelle, MD, Samaniego, Felipe, MD, Feng, Lei, MS, Baladandayuthapani, Veerabhadran, PhD, Wang, Zhiqiang, PhD, Ma, Wencai, PhD, Gao, Yanli, MS, Wallace, Michael, Prof, Vence, Luis M, PhD, Radvanyi, Laszlo, Prof, Muzzafar, Tariq, MD, Rotem-Yehudar, Rinat, PhD, Davis, R Eric, MD, Neelapu, Sattva S, Dr

“…Summary Background Endogenous or iatrogenic antitumour immune responses can improve the course of follicular lymphoma, but might be diminished by immune…”
Get full text

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial by Neelapu, Sattva S., Dickinson, Michael, Munoz, Javier, Ulrickson, Matthew L., Thieblemont, Catherine, Oluwole, Olalekan O., Herrera, Alex F., Ujjani, Chaitra S., Lin, Yi, Riedell, Peter A., Kekre, Natasha, de Vos, Sven, Lui, Christine, Milletti, Francesca, Dong, Jinghui, Xu, Hairong, Chavez, Julio C.

“…High-risk large B-cell lymphoma (LBCL) has poor outcomes with standard first-line chemoimmunotherapy. In the phase 2, multicenter, single-arm ZUMA-12 study…”
Get full text

Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma by Strati, Paolo, Varma, Ankur, Adkins, Sherry, Nastoupil, Loretta J, Westin, Jason, Hagemeister, Fredrick B, Fowler, Nathan H, Lee, Hun J, Fayad, Luis E, Samaniego, Felipe, Ahmed, Sairah, Chen, Yiming, Horowitz, Sandra, Arafat, Sara, Johncy, Swapna, Kebriaei, Partow, Mulanovich, Victor Eduardo, Ariza Heredia, Ella, Neelapu, Sattva S

“…Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 may be associated with long-term adverse effects such as cytopenia and immune deficiency. In…”
Get full text

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma by Locke, Frederick L., Neelapu, Sattva S., Bartlett, Nancy L., Siddiqi, Tanya, Chavez, Julio C., Hosing, Chitra M., Ghobadi, Armin, Budde, Lihua E., Bot, Adrian, Rossi, John M., Jiang, Yizhou, Xue, Allen X., Elias, Meg, Aycock, Jeff, Wiezorek, Jeff, Go, William Y.

“…Outcomes for patients with refractory diffuse large B cell lymphoma (DLBCL) are poor. In the multicenter ZUMA-1 phase 1 study, we evaluated KTE-C19, an…”
Get full text